For Sponsors
Site Capabilities
Trial infrastructure across our North Miami Beach clinical trial site and heart practice, our new Kendall office, and the Kendall cardiovascular surgery center. Cardiovascular core, plus nephrology and neurology studies.
Amavita Research operates inside amavita Heart and Vascular Health®, a full-service cardiology practice with on-site procedural and diagnostic infrastructure. The same physicians who serve as Principal Investigators on trials see cardiology patients every business day, which gives the site continuous patient flow and immediate access to procedural resources. Below is a summary of the infrastructure available to sponsors for cardiovascular feasibility, pivotal, and first-in-human protocols.
Looking for the process side — feasibility, start-up, enrollment, conduct, monitoring, and close-out? See Trial Services →
Cardiovascular research is our core, and our site now also takes on nephrology and neurology studies with affiliated investigators: nephrologist Dr. Robenson Jean-Marie and neurologist Dr. Delores Macksoud. Immunology and oncology are expansion areas through imaging-enabled subcontracted scopes, with Amavita as prime contractor and our affiliated imaging partner performing imaging. We are now recruiting partner practices in oncology, neurology, immunology, gastroenterology, rheumatology and other areas. Oncology expansion · Neurology expansion
Procedural capabilities
- Cardiac catheterization lab
- Direct access to amavita Heart and Vascular Health® cath-lab and the affiliated Advanced Cardiovascular of Miami ambulatory surgical center. Coronary angiography, PCI, IVUS, OCT, peripheral angiography, peripheral atherectomy.
- Electrophysiology
- Triple-board-certified EP on staff (Dr. Hans C. Rutzen-Lopez, MD). Capability for AFib screening protocols, ICD/CRT-D device follow-up, ECG-gated trial assessments.
- Structural heart consultation
- Dr. William W. O'Neill, MD, FACC — structural heart leadership (TAVR/Impella legacy). Consultative role on high-acuity structural protocols.
- Peripheral intervention
- Below-the-knee atherectomy capability via PI Dr. Pedro Martinez-Clark, MD, FACC. Active Phase 3 PAD trial enrollment (GREAT/Golazo®).
- IV infusion suite
- On-site IV infusion bays for trial dosing protocols (e.g., IV ferric derisomaltose, IV inotropes, IV diuretics). Trained CRC supervision.
- Subcutaneous and oral dosing
- Routine SC/PO trial dosing under PI supervision; dose-administration logs maintained per ICH-GCP.
Diagnostic capabilities
- Echocardiography
- Transthoracic echo on-site; transesophageal echo via affiliated facility. Sponsor-provided core-lab transmission supported.
- Ambulatory blood pressure monitoring
- 24-hour ABPM available for hypertension protocols (e.g., ZENITH zilebesiran).
- ECG (12-lead and Holter)
- 12-lead ECG on every clinic visit; 24-hour, 48-hour, and event-monitor Holter available. Sponsor-provided central ECG-reading supported.
- Cardiac biomarkers
- Same-day venous draws for NT-proBNP, troponin, hs-CRP. Central-lab kit handling and sample shipping per IATA training.
- Imaging coordination
- Cardiac CT and cardiac MRI scheduled via affiliated imaging centers; direct integration with sponsor imaging core labs.
- FibroScan
- Coming soon: in-office FibroScan® (VCTE) liver stiffness assessment, to support protocol-specified liver assessments in cardiometabolic studies.
Operational capabilities
- IRB strategy
- Central IRB preferred (WCG, Advarra). Site has experience with both. Local IRB also available if sponsor requires.
- Contract execution
- Standard CTA template available; turnaround depends on the number of changes each side needs and on budget review.
- Source documentation
- EHR + dedicated trial source documents per protocol. eSource-compatible.
- Monitoring
- On-site and remote monitoring supported. Dedicated CRC workspace with secure network access.
- Drug accountability
- Temperature-monitored IP storage; chain-of-custody logs; on-site sponsor-monitored IP destruction or return shipping.
- Patient retention
- In-network cardiology practice means patients are already attached to the practice for routine cardiology care — drop-out rates lower than database-recruited cohorts.
Quality and compliance
- IAOCR GCSA-certified (recertified May 13, 2026, valid to Feb 28, 2027) (GCSA-certified (recertified May 13, 2026, valid to Feb 28, 2027))
- ICH-GCP E6(R3) compliant
- SCRS (Society for Clinical Research Sites) member
- HIPAA-compliant patient handling; BAA-ready for sponsor data exchange
- Spanish/Haitian Creole/Portuguese bilingual staff for Miami's multilingual patient population
Sub-specialty coverage
- Interventional cardiology — Dr. Pedro Martinez-Clark, MD, FACC (bio →)
- Coronary stent at a dedicated cardiovascular ambulatory surgery center (ASC) in Miami-Dade (May 2026) — Read about the first coronary stent in a Miami-Dade ASC
- Electrophysiology — Dr. Hans C. Rutzen-Lopez, MD (bio →)
- Structural heart consultation — Dr. William W. O'Neill, MD, FACC (bio →)
- Heart failure — Dr. Pedro Martinez-Clark, MD, FACC (CYCLE heart failure trial, CHAMP-HF Registry) (bio →)
- General cardiology and trial co-management — Yasnaya Cruz-Santiago, APRN; Orlando Ortega-Izquierdo, APRN (bio · bio)
Cross-border trial designs
Sponsors running U.S.-Latin America hybrid protocols can integrate Amavita Research as the U.S. arm and bioaccess® as the Latin America arm under a single coordinated design. bioaccess® is the first-in-human CRO for the Americas with operations in Colombia and other regional markets. Julio G. Martinez-Clark, CEO of bioaccess® and Chief Executive Officer (CEO) of Amavita Research, coordinates these dual-region engagements.
New: Need a Latin America arm too? Read our cross-border strategy guide →
Cardiometabolic and MASH feasibility
Many cardiovascular patients also live with type 2 diabetes, obesity, or metabolic dysfunction-associated steatotic liver disease (MASLD/MASH). Amavita Research Services, a GCSA-certified cardiovascular clinical trial site in Miami, is adding in-office FibroScan® (vibration-controlled transient elastography, VCTE) liver stiffness assessment, coming soon. It is intended to support protocol-specified liver assessments in cardiometabolic studies and trials that look at heart and liver disease together. Sponsors are welcome to share their feasibility questionnaires with our team.